FDA Nod for Inflammation Drug Notches Wins for Rare Disease Patients, Roivant’s Biz Strategy
Roivant Sciences subsidiary Priovant Therapeutics received FDA approval for Lisraya as a treatment for the rare inflammatory disorder dermatomyositis. Licensed from Pfizer, this once-daily pill designed to block JAK1 and TYK2 proteins is also in clinical development for three additional rare immunological disorders, each with blockbuster potential.